• Royalty Pharma PLC RPRX.OQ reported quarterly adjusted earnings of 65 cents​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of 98 cents. The mean expectation of five analysts for the quarter was for earnings of $1.59 per share. Wall Street expected results to range from 86 cents to $4.13 per share.

• Revenue held steady 0% to $568.00 million from a year ago; analysts expected $705.34 million.

• Royalty Pharma PLC's reported EPS for the quarter was 41 cents​.

• Royalty Pharma PLC shares had risen by 5.2% this quarter and gained 28.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 49.1% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Royalty Pharma PLC is $40.00

This summary was machine generated from LSEG data May 8 at 02:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)